Bovie Medical Corporation
FINANCIALS
 

Financial Profile
 
 
2016   |   2015   |   2014   |   2013   |   2012   |   2011   |   2010   |   2009   |   2008   |   
2007   |   2006   |   2005   |   2004   |   2003   |   2002   |   2001   |   2000
 

BOVIE MEDICAL CORPORATION ANNOUNCES FIRST QUARTER 2016 EARNINGS CALL

CLEARWATER, FL – April 27, 2016 – Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that it will issue its financial results for the first quarter ended March 31, 2016 on Wednesday May 11, 2016 before market open.

Management will host a conference call on Wednesday May 11, 2016 at 8:30am Eastern Time to discuss latest corporate developments. Following management’s formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 866-320-0174. International callers should call 785-424-1631. Participants should ask for the Bovie Medical Corporation Call. The conference call will also be available through a live webcast at Bovie Medical Corporation’s website or at http://www.investorcalendar.com/IC/CEPage.asp?ID=174975

A replay of the call will be available approximately two hours after the end of the call through June 11, 2016. The replay can be accessed via Bovie Medical Corporation’s website or by dialing 877-481-4010 for U.S. callers or 919-882-2331 for International callers and using the replay access code 10025.

 


About Bovie Medical Corporation

BBovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

 

Investor Relations:
MBS Value Partners
Hugh Collins
(212) 223-4632 
investor.relations@boviemed.com




BOVIE MEDICAL CORPORATION ANNOUNCES LAUNCH OF J-PLASMA® PRECISE 360
AND ITS APPLICATION IN PROSTATE SURGERY PROCEDURES

CLEARWATER, FL – April 20, 2016 - Bovie Medical Corporation, a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced the launch of its J-Plasma® product extension, branded the Precise 360.

This new J-Plasma® hand piece has an angled and rotating tip that enables surgeons access to structures that are difficult to reach using a straight laparoscopic device.  

One of the first surgeons to use the Precise 360 is Vipul Patel, MD, a world-renowned urologist and leader in robotic surgery and a member of Bovie’s Medical Advisory Board. Dr. Patel is the head of the Global Robotics Institute at Florida Hospital in Orlando and has personally performed over 9,000 robotic prostatectomies.

Commenting on Precise 360, Dr. Patel said, “By inserting the new angle tip of the Precise 360™ in the ancillary port of the DaVinci robot, the surgeon gains greater access, control and precision than the straight stick versions. With this level of precision, control and safety, J-Plasma has the potential to become a standard of care in a range of procedures.”

J-Plasma®, Bovie’s transformational surgical product, enables surgeons to operate with greater precision on and around delicate structures with minimal thermal spread. The Precise 360 extension builds on last year’s additions to the J-Plasma® portfolio, which includedblade and needle configurations in three different instrument lengths.

“We continue to innovate J-Plasma® to address specific procedures for which it is particularly well-suited,” said Robert L. Gershon, Chief Executive Officer. “The next J-Plasma® portfolio additions will include a configuration specifically designed for use in robotic surgery, developed in close collaboration with Bovie’s Medical Advisory Board, which in addition to Dr. Patel, is comprised of two prominent robotic surgeons in the fields of cardiovascular and cardiothoracic surgery.”


About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

 

Investor Relations:
MBS Value Partners
Hugh Collins
(212) 223-4632 
investor.relations@boviemed.com




BOVIE MEDICAL CORPORATION REPORTS 
FOURTH QUARTER AND FULL YEAR 2015 RESULTS

2015 Highlights

-Sales increased 6.6% to $29.5 million
-Gross margin expanded 180 basis points to 42.4%, from adjusted gross margin of 38.7% in 2014
- J-Plasma® sales reached $1.3 million, up from $209,000 in 2014
 -Higher OEM activity in 2015 should benefit 2016 results

J-Plasma® Operating Metrics

-81 generators-in-use at end of 2015, up from 18 at end of 2014
-61 additional Scrub Purchase Orders (POs) in the fourth quarter; full year Scrub POs totaled 182
-151 surgeons using J-Plasma® at year-end, up from 32 at end of 2014
-Hand piece sales volumes up 28% sequentially in Q4 vs. Q3
-Hospital VAC approvals rise to 71; 57 additional VACs reviewing the product. VAC acceptance rate is over 92%

CLEARWATER, FL — MARCH 17, 2016- Bovie Medical Corporation (NYSEMKT:BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced results for the fourth quarter and full year ended December 31, 2015.

Management Comments

“2015 was a year of solid execution and has laid the foundation for growth in 2016,” said Robert L. Gershon, Chief Executive Officer.  “Surgeon demand and use of our transformational J-Plasma® product reached record levels in 2015. We posted progressive increases in hand piece sales volumes throughout the year, with fourth quarter hand piece sales volumes increasing 28% sequentially over third quarter levels. J-Plasma® generator sales, however, continued to lag our expectations, reflecting industrywide trends of longer sales cycles for capital equipment purchases.

Key 2015 Accomplishments Included:

    • Strong growth in J-Plasma® sales; even more impressive are the number of procedures that have been done using the J-Plasma® product, which we estimate reached over 1,300 in 2015; The rate of hospital VAC approvals for use of J-Plasma® exceeded  92% for the year, reflecting the safety, ease-of-use and cost effectiveness of the product.
    • Consistent mid-single digit growth in our core business, leveraging Bovie’s unique brand  reputation and demand from the industry’s  leading  medical technology companies  for Bovie’s manufacturing expertise;
    • The formation of a Medical Advisory Board for J-Plasma®, consisting of world-renowned experts in several different specialties; this marks the first step  in  J-Plasma® ’s rollout into fields beyond our initial target specialties of gynecology and plastic surgery; and
    • The acquisition of Bovie Bulgaria, our long-standing R&D and manufacturing contractor, in order to strengthen our supply chain and achieve product development efficiencies.
“The leading indicators of future J-Plasma® sales trends progressively increased in 2015 and ended the year with substantial positive momentum. Specifically, those that most closely track surgeon adoption of J-Plasma®, generators-in-use and scrub POs, were up more than two-fold and three-fold, respectively, in the second half of 2015 compared to the first half of the year.”

 
Fourth Quarter 2015 Results

Fourth quarter sales were $8.3 million, an 11.1% increase from $7.5 million in the fourth quarter of 2014.

Gross profit was $3.5 million compared with $2.4 million in the fourth quarter of 2014. Gross margin was 42.4%, a significant improvement over the adjusted gross margin of 38.7% and reported gross margin of 32.7% of last year’s fourth quarter.

Operating loss for the quarter was $1.4 million, lower on both a sequential and a year-over-year basis. Higher gross profit more than offset increased operating expenses associated with J-Plasma®’s commercialization.

Net loss attributable to common shareholders for the period was $1.4 million, or $0.05 per diluted share, compared with a loss of $5.5 million, or $0.39 per diluted share, in the fourth quarter of 2014. Results for the fourth quarter of 2014 included a non-cash gain of $2.5 million related to the mark-to-market accounting for the fair value of issued common stock purchase warrants, as well as a non-cash charge of $6.0 million on the write down of a deferred tax asset.

Full Year 2015 Results

For full year 2015, total sales were up 6.6% over the prior year to $29.5 million.

Gross Profit rose 39.6% to $12.6 million from 2014. Gross margin reached 42.5%, a significant improvement from last year’s adjusted gross margin of 40.7% and the reported 32.5% gross margin.

Operating loss in 2015 was $7.0 million compared with $5.8 million in 2014, as a result of higher operating expenses related to the Company’s growth investments to commercialize J-Plasma® and expand its product and patent portfolios. In the aggregate, these initiatives accounted for more than 60% of the $4.7 million year-on-year increase in operating expenses.

The Company reported net income of $8.4 million, or $0.24 per diluted share compared to a net loss of $18.2 million or $1.03 per diluted share last year. 2015 net income benefited from a gain on conversion of warrants and preferred shares of $14.0 million and a change in fair value of derivative liabilities of $1.8 million; in 2014, the Company incurred a loss of $7.3 million from the change in fair value of derivative liabilities.  

At the end of 2015, the Company had unrestricted cash and cash equivalents $11.8 million, compared to $5.7 million at the end of 2014.

Summary and Outlook

“Looking ahead, we intend to build upon the progress made in 2015 to achieve meaningful growth in 2016.

“We see continued low to mid-single digit growth in our core business coming from steady demand for Bovie’s signature core products, and from the addition of new products. we remain one of the premier names in the OEM space, and we entered 2016 with an active pipeline of new orders and the ability to capture additional market share.

“J-Plasma® product sales should accelerate substantially in 2016. We have a pipeline of 128 hospitals where the product has been approved or under review; the expert surgeons who comprise our Medical Advisory Board are guiding us in expanding the size and scope of J-Plasma®’s  addressable market ; and together with other top surgeons and leaders in robotic surgery, our Advisory Board members  are currently investigating which procedures in their respective specialties support the use of J-Plasma and its potential adoption as a “standard of care” in their  respective fields of urology, cardiovascular and cardiothoracic surgery. Based on this pipeline of activity and our leading indicators of adoption, we expect J-Plasma® hand piece volumes to increase by nearly 3x in 2016.

“The anticipated growth in core business sales and J-Plasma®, underpinned by the operating expense savings we expect from last year’s acquisition of Bovie Bulgaria and by our own financial discipline, should enable us to achieve breakeven cash flow by the end of the fourth quarter of this year,” Mr. Gershon concluded. 

Conference Call Details

The Company’s management will host a conference call on Thursday, March 17, 2016 at 5:00pm Eastern Time to discuss the latest corporate developments. Following management’s formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-888-349-0106. International callers should call 1-412-902-0131. All parties should ask for the Bovie Medical Corporation call. The conference call will also be available through a live webcast at Bovie Medical Corporation’s website or at http://services.choruscall.com/links/bvx160317

A replay of the call will be available approximately one hour after the end of the call through March 31, 2016. The replay can be accessed via Bovie Medical Corporation’s website or by dialing 1-877-344-7529 for U.S. callers or 1-412-317-0088 for International callers and using the replay access code 10081682.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s www.boviemed.com

Use of Non-GAAP Financial Measures


In this press announcement, management has disclosed financial measurements that present financial information not in accordance with Generally Accepted Accounting Principles (GAAP). These measurements are not a substitute for GAAP measurements, although company management uses these measurements as aids in monitoring the company's ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies. Adjusted non-GAAP gross margin, adjusted non-GAAP income from operations, adjusted non-GAAP net income and adjusted non-GAAP income per diluted share measure the gross margin, income from operations, net income and income per diluted share of the company excluding unusual items. Management uses and presents these measures because management believes that such adjustments facilitate an understanding of the financial impact of unusual items on the company's short- and long-term financial trends. Management also uses adjusted non-GAAP items to forecast and to evaluate the operational performance of the company, as well as to compare results of current periods to prior periods on a consistent basis.

Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly-titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Please refer to the attached reconciliation between GAAP and non-GAAP financial measures.

Cautionary Statement on Forward-Looking Statements

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Forms 10-K and 10-Q for the year ended December 31, 2014 and the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015, respectively.   For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

 

      

 

 

      

 

 

      

 

 

      

 

Investor Relations:
MBS Value Partners
Hugh Collins
(212) 223-4632 
investor.relations@boviemed.com


BOVIE MEDICAL HIRES DIRECTOR OF MARKETING AND TWO NEW REGION MANAGERS

CLEARWATER, FL - March 4, 2016 - Bovie Medical, a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced the hire of a Director of Marketing and two new Region Managers for its J-Plasma® product line.

Bovie’s new Director of Marketing, Jeffrey Hoffman, is an experienced medical device executive with significant marketing and sales expertise, as well as specialized knowledge in advanced energy technology, including plasma.

Prior to joining Bovie, Mr. Hoffman was Director of Global Marketing and Product Management at Plasma Surgical and held several executive positions during his 13-year tenure at CryoLife/ CryoLife Europa where he oversaw global strategy development, marketing and product management for specialized product lines.

Commenting on this appointment, Robert L. Gershon, Chief Executive Officer noted, “We are pleased to have Jeff on board and expect him to play an important role in increasing and broadening nationwide adoption of J-Plasma® as well as supporting product launches and other revenue-generating activities within our Core business.”

In addition, the Company has hired two Region Managers, Robert Timerman and Dennis Keast, to help advance the adoption of J-Plasma® and oversee the product’s expanding geographic sales footprint. Mr. Timerman will be responsible for the Eastern U.S. while Mr. Keast will oversee the Central U.S.

Mr. Timerman has extensive medical device sales experience, having held senior positions at companies including CryoLife, BrainLAB, Biomet Orthopedics and Smith & Nephew.

Prior to joining Bovie, Mr. Keast was Regional Sales Director at Cardiva Medical, and has held senior sales and business development roles at companies including Covidien, KCI, Nova Biomedical and Sakura Finetek USA.

“Robert and Dennis will be charged with accelerating J-Plasma® sales in their respective regions, building upon the progress we have already made in gaining surgeon adoption and hospital VAC approvals. In addition, we continue to build a highly-credentialed direct sales force to drive accelerated product sales in 2016 and beyond, Mr. Gershon said.

Messieurs Hoffman, Timerman and Keast will each receive an inducement grant of 20,000 shares of Bovie Medical stock with a four (4) year vesting period. The option strike prices will equal the closing price of Bovie shares as of the close of trade today.


About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

 

Investor Relations:
MBS Value Partners
Hugh Collins
(212) 223-4632 
investor.relations@boviemed.com




BOVIE MEDICAL ANNOUCES FOURTH QUARTER AND FULL YEAR 2015 EARNINGS CALL

CLEARWATER, FL - February 23, 2016 - Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2015 on Thursday March 17, 2016 after market close.

Management will host a conference call on Thursday March 17, 2016 at 5:00pm Eastern Time to discuss latest corporate developments. Following management’s formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-888-349-0106. International callers should call 1-412-902-0131. All parties should ask for the Bovie Medical Corporation call. The conference call will also be available through a live webcast at Bovie Medical Corporation’s website or at http://services.choruscall.com/links/bvx160317

A replay of the call will be available approximately one hour after the end of the call through June 2, 2016. The replay can be accessed via Bovie Medical Corporation’s website or by dialing 1-877-344-7529 for U.S. callers or 1-412-317-0088 for International callers and using the replay access code 10081682.


About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

 

Investor Relations:
MBS Value Partners
Hugh Collins
(212) 223-4632 
investor.relations@boviemed.com




BOVIE MEDICAL ANNOUCES COMPLETION OF NEW J-PLASMA® WHITE PAPERS

- New white papers cover range of procedures, including breast capsule treatment and ablation of intra-abdominal adhesions

- 10 white papers published on J-Plasma® to date

- Company also announces plans to launch the Precise 360TM handpiece for J-Plasma® in Q2 of this year

CLEARWATER, FL - January 11, 2016 - Bovie Medical, a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced the completion and availability of several new white papers on J-Plasma®.

The white papers highlight the application of J-Plasma® for procedures including breast capsule scoring and the treatment of intra-abdominal adhesions within the plastic surgery and gynecology specialties. Additionally, a detailed article was written documenting the use of J-Plasma® to treat rhinophyma, a complication associated with rosacea that can seriously impede a patient’s ability to breathe.

These white papers increase the total number of white papers on J-Plasma® to 10, in line with the Company’s stated goal. A selection of the white papers is available on the Bovie Medical website: www.boviemedical.com

“J-Plasma® is a unique and powerful tool for a range of minimally-invasive surgeries,” said Robert L. Gershon, Chief Executive Officer. These white papers are further evidence of its benefits for surgeons performing a wide variety of procedures, and they support our stated objective of developing J-Plasma® into the standard of care for specific surgeries across a growing number of practice areas. We are pleased to have reached our objective of 10 white papers. We expect additional white papers and clinical studies to be issued throughout 2016 as we continue the commercialization of J-Plasma® and increase the number of new surgeons using the product.”

Highlights from the white papers include:

  • An alternate approach to breast capsule scoring compared to traditional cautery techniques in a paper by Dr. Vip Dev of the California Institute of Cosmetic & Reconstructive Surgery. This paper noted J-Plasma® could reduce muscle trauma, and initial results suggest beneficial effects on capsular contracture rates, pain, and hematoma formation.
  • J-Plasma®’s role in treating and preventing intra-abdominal adhesions, in a paper by Dr. Craig E. McCoy of the Women’s Wellness Center in Columbia, Missouri. Abdominal adhesions are an expensive surgical byproduct lacking effective prevention. J-Plasma® was found to be safe, precise and economical in adhesion treatment and the reduced thermal tissue damage may play a role in adhesion prevention.
  • The surgical treatment of endometriosis in a paper by Dr. Mario Nutis of the Center for Special Minimally Invasive & Laser Gynecologic Surgery. Dr. Nutis noted that the greater precision offered by J-Plasma® lessened tissue damage, reduced his patients preoperative symptoms, and provided treatment at a reasonable cost.
  • A case study on rhinophyma. This paper described the treatment of rhinophyma with J-Plasma®. The surgical precision and reduced tissue damage offered by J-Plasma was instrumental in a successful outcome that ultimately enabled the patient to breath clearly and enabled the surgeon to blend tissue seamlessly for improved cosmetic result.

Launch of Precise 360 Handpiece

Bovie also announced today that the launch of the latest J-Plasma® product extension, the Precise 360 handpiece will occur in Q2 of this year. The Precise 360 has a rotating tip that will enable surgeons to navigate structures that may be difficult to access using a typical straight laparoscopic device. This launch follows the successful commercialization of six new handpiece configurations in September of 2015.

“This new handpiece builds on J-Plasma®’s great advantage, namely precision,” Mr. Gershon said. “This launch highlights Bovie’s ability to efficiently develop new, complementary product extensions that improve the surgeon’s experience using J-Plasma® for an expanding universe of minimally invasive procedures.”


About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

 

Investor Relations:
MBS Value Partners
Hugh Collins
(212) 223-4632 
investor.relations@boviemed.com




BOVIE MEDICAL CORPORATION TO PARTICIPATE IN BIOTECH SHOWCASE 2016

CLEARWATER, FL — January 6, 2016Bovie Medical Corporation (“Bovie” or the “Company”) (NYSE: BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today that Robert L. Gershon, Chief Executive Officer of the Company, and Jack McCarthy, Chief Commercialization Officer, will participate in the 8th Annual Biotech Showcase Conference in San Francisco.

The conference will be held at the Parc 55 Hotel in San Francisco, where Mr. Gershon will present to investors on Monday, January 11 at 2.30pm PST, 2016. Mr. Gershon will discuss the Company and J-Plasma®, its transformational surgical product.

This presentation will be webcast at http://www.boviemedical.com/financials.asp

Mr. Gershon will also present at Medtech Showcase, which is part of the Biotech Showcase conference, on Tuesday, January 12 at 10am PST, 2016.

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to and meet with investors and industry executives. If you would like to schedule a one-on-one meeting with Bovie Medical management at the event, please register and proceed through the event's partnering system or contact MBS Value Partners


About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.

 

Investor Relations:
Hugh Collins
MBS Value Partners
(212) 223-4632 
investor.relations@boviemed.com




         
 
   
   
$ 0.09